Physician profile
Zheni Avram
NPI 1215113196
$4,070.97
in general payments reported to CMS, 2019-2025
42 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $265 · 2021: $274 · 2022: $820 · 2023: $734 · 2024: $1,003 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,278.05 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $695.70 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $204.25 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Insightec,INC | $149.64 | 2023-2024 | Exablate |
| Glaxosmithkline, LLC. | $145.70 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $139.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.47 | 2020-2023 | Jardiance |
| Abbott Laboratories | $112.82 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Inspire Medical Systems, INC. | $96.78 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $83.02 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $80.58 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $75.13 | 2020-2024 | Farxiga |
| Amgen INC. | $72.49 | 2019-2025 | Repatha |
| Lilly USA, LLC | $69.72 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $66.20 | 2023-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zheni Avram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.